Monte Rosa Therapeutics, Inc. GLUE Continuing operations (in dollars per share)
Continuing operations (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncomeLossFromContinuingOperationsPerBasicShare.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s continuing operations (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s continuing operations (in dollars per share)?
- Monte Rosa Therapeutics, Inc. (GLUE) reported continuing operations (in dollars per share) of -$0.45 in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s continuing operations (in dollars per share) changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s continuing operations (in dollars per share) decreased by 178.9% year-over-year, from $0.57 to -$0.45.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s continuing operations (in dollars per share)?
- Over 2 years (2022 to 2025), Monte Rosa Therapeutics, Inc.'s continuing operations (in dollars per share) has grown at a -55.2% compound annual growth rate (CAGR), from -$2.29 to -$0.46.